These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27389672)

  • 1. Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States.
    Maust DT; Bonar EE; Ilgen MA; Blow FC; Kales HC
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1000-1003. PubMed ID: 27389672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of State Policies Allowing Medical Cannabis for Opioid Use Disorder With Dispensary Marketing for This Indication.
    Shover CL; Vest NA; Chen D; Stueber A; Falasinnu TO; Hah JM; Kim J; Mackey I; Weber KA; Ziadni M; Humphreys K
    JAMA Netw Open; 2020 Jul; 3(7):e2010001. PubMed ID: 32662844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical marijuana: Legal and regulatory considerations.
    Kaplan L
    Nurse Pract; 2015 Oct; 40(10):46-54; quiz 54-5. PubMed ID: 26383024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical marijuana: Legal considerations for physicians.
    Martin J
    Med Econ; 2015 Dec; 92(23):43-4. PubMed ID: 26875333
    [No Abstract]   [Full Text] [Related]  

  • 5. Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017.
    Klieger SB; Gutman A; Allen L; Pacula RL; Ibrahim JK; Burris S
    Addiction; 2017 Dec; 112(12):2206-2216. PubMed ID: 28696583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Ethical Framework to Manage Patient Requests for Medical Marijuana.
    Redinger M; Fledderman N; Crutchfield P
    J Am Board Fam Med; 2020; 33(1):147-151. PubMed ID: 31907257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Policy Responses to Calls for the Medical Use of Cannabis.
    Hall W
    Yale J Biol Med; 2015 Sep; 88(3):257-64. PubMed ID: 26339208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cannabis politics - but truthful].
    Kappert-Gonther K
    MMW Fortschr Med; 2016 May; 158(10):40. PubMed ID: 27221425
    [No Abstract]   [Full Text] [Related]  

  • 9. Medical Marijuana.
    Capriotti T
    Home Healthc Now; 2016 Jan; 34(1):10-5. PubMed ID: 26645838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
    Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
    Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis.
    Stahl SM
    CNS Spectr; 2018 Oct; 23(5):291-297. PubMed ID: 30382934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Experiences of Medical Marijuana Patients: A Scoping Review of the Qualitative Literature.
    Ryan J; Sharts-Hopko N
    J Neurosci Nurs; 2017 Jun; 49(3):185-190. PubMed ID: 28471927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine treatment of agitation associated with dementia.
    Leibovici A; Tariot PN
    J Geriatr Psychiatry Neurol; 1988; 1(2):110-2. PubMed ID: 3252879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Re)introducing medicinal cannabis.
    Mather LE; Rauwendaal ER; Moxham-Hall VL; Wodak AD
    Med J Aust; 2013 Dec; 199(11):759-61. PubMed ID: 24329652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series.
    Devanand DP; Pelton GH; D'Antonio K; Strickler JG; Kreisl WC; Noble J; Marder K; Skomorowsky A; Huey ED
    Alzheimer Dis Assoc Disord; 2017; 31(1):73-75. PubMed ID: 27819842
    [No Abstract]   [Full Text] [Related]  

  • 17. Dispensaries: the Wild West of Vancouver.
    Lough S
    CMAJ; 2015 Aug; 187(11):E345-E346. PubMed ID: 26195580
    [No Abstract]   [Full Text] [Related]  

  • 18. The Impact of Legalizing and Regulating Weed: Issues with Study Design and Emerging Findings in the USA.
    Hunt PE; Miles J
    Curr Top Behav Neurosci; 2017; 34():173-198. PubMed ID: 26718590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.
    Phillips JA; Holland MG; Baldwin DD; Gifford-Meuleveld L; Mueller KL; Perkison B; Upfal M; Dreger M
    Workplace Health Saf; 2015 Apr; 63(4):139-64. PubMed ID: 25862727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia.
    Postgrad Med; 1998 Apr; Spec No():1-88. PubMed ID: 9585819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.